Novabay Pharmaceuticals (NBY)
XASE:NBY
NBY Stock Chart & Stats
$2.95
-$0.04(-5.41%)
At close: 4:00 PM EST
$2.95
-$0.04(-5.41%)
Day’s Range― - ―
52-Week Range$1.11 - $99.75
Previous CloseN/A
Volume41.84K
Average Volume (3M)662.09K
Market Cap
$39.94M
Enterprise Value$32.76M
Total Cash (Recent Filing)$7.96M
Total Debt (Recent Filing)$776.00K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,625,029
10 Day Avg. Volume978,608
30 Day Avg. Volume662,089
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-7.19
Price to Sales (P/S)0.00
P/FCF Ratio-19.47
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$15.80M
Bulls Say, Bears Say
Bulls Say
Asset SaleNovaBay accepted an increased offer of $11.5 million for its Avenova assets, which may benefit the company's financial position.
Business StrategyThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Bears Say
Financial PerformanceNet loss was $1.6 million or EPS of $(1.37) compared with our estimates of $(1.28) and consensus of $(1.23).
Investor UncertaintyThe company did not provide 2024 guidance, which creates uncertainty for investors.
Revenue PerformanceRevenue was $2.4 million compared with our estimates of $2.8 million and consensus of $3.2 million.
NovaBay Pharma News
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $1.11 and its highest was $99.75 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Novabay Pharmaceuticals’s market cap is $39.94M.
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Overvalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals pays a Notavailable dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Novabay Pharmaceuticals dividends here
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 26,625,029 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBay Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
NBY Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.44%
12-Months-Change
Fundamentals
Return on Equity
821.56%
Trailing 12-Months
Asset Growth
-10.06%
Trailing 12-Months
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Technical Analysis
Soligenix
―
Jaguar Animal Health
―
Evaxion Biotech
―
SciSparc Ltd.
―
60 Degrees Pharmaceuticals, Inc.
―